{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T08:20:18Z","timestamp":1783239618553,"version":"3.54.6"},"reference-count":42,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007109","name":"Universit\u00e0 degli Studi di Ferrara","doi-asserted-by":"publisher","award":["FIR1753939"],"award-info":[{"award-number":["FIR1753939"]}],"id":[{"id":"10.13039\/501100007109","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007109","name":"Universit\u00e0 degli Studi di Ferrara","doi-asserted-by":"publisher","award":["FIR1618189"],"award-info":[{"award-number":["FIR1618189"]}],"id":[{"id":"10.13039\/501100007109","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["RBAP11Z4Z9_002"],"award-info":[{"award-number":["RBAP11Z4Z9_002"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>In B-chronic lymphocytic leukemia (B-CLL), the interaction between leukemic cells and the microenvironment promotes tumor cell survival. The Bruton\u2019s tyrosine kinase (BTK) inhibitor ibrutinib is one of the first-in-class molecules for the treatment of B-CLL patients; however, the emerging mechanisms of resistance to ibrutinib call for new therapeutic strategies. The purpose of the current study was to investigate the ability of ibrutinib plus the MDM2-inhibitor nutlin-3 to counteract the tumor microenvironment protective effect. We observed that primary B-CLL cells cultivated in microenvironment mimicking conditions were protected from apoptosis by the up-regulation of c-MYC and of p53. In the same setting, combined treatments with ibrutinib plus nutlin-3 led to significantly higher levels of apoptosis compared to the single treatments, counteracting the c-MYC up-regulation. Moreover, the combination induced high p53 levels and a significant dissipation of the mitochondrial membrane potential, together with BAX cleavage in the more active p18 form and phospho-BAD down-regulation, that are key components of the mitochondrial apoptotic pathway, enhancing the apoptosis level. Our findings propose a new therapeutic strategy to overcome the tumor microenvironment protection involved in B-CLL resistance to drugs, with possible clinical implications also for other hematologic and solid tumors for which ibrutinib is considered a therapeutic option.<\/jats:p>","DOI":"10.3390\/curroncol28040223","type":"journal-article","created":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T12:03:27Z","timestamp":1625141007000},"page":"2439-2451","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Overcoming of Microenvironment Protection on Primary Chronic Lymphocytic Leukemia Cells after Treatment with BTK and MDM2 Pharmacological Inhibitors"],"prefix":"10.3390","volume":"28","author":[{"given":"Erika","family":"Rimondi","sequence":"first","affiliation":[{"name":"Department of Translational Medicine and LTTA Centre, University of Ferrara, 44121 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7829-0824","authenticated-orcid":false,"given":"Elisabetta","family":"Melloni","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine and LTTA Centre, University of Ferrara, 44121 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8000-6178","authenticated-orcid":false,"given":"Arianna","family":"Romani","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine and LTTA Centre, University of Ferrara, 44121 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8448-066X","authenticated-orcid":false,"given":"Veronica","family":"Tisato","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine and LTTA Centre, University of Ferrara, 44121 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6431-3335","authenticated-orcid":false,"given":"Fabio","family":"Casciano","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine and LTTA Centre, University of Ferrara, 44121 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Matteo","family":"Rigolin","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Medical Sciences, University of Ferrara, 44122 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9540-7801","authenticated-orcid":false,"given":"Daniela","family":"Milani","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Celeghini","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Zauli","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Secchiero","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine and LTTA Centre, University of Ferrara, 44121 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6747-3465","authenticated-orcid":false,"given":"Rebecca","family":"Voltan","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine and LTTA Centre, University of Ferrara, 44121 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,7,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.beha.2016.08.007","article-title":"The chronic lymphocytic leukemia microenvironment: Beyond the B-cell receptor","volume":"29","author":"Choi","year":"2016","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.3324\/haematol.2016.142679","article-title":"Chronic lymphocytic leukemia cells are active participants in microenvironmental cross-talk","volume":"102","author":"Eldering","year":"2017","journal-title":"Haematologica"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.neo.2017.07.004","article-title":"The stromal microenvironment modulates mitochondrial oxidative phosphorylation in chronic lymphocytic leukemia cells","volume":"19","author":"Vangapandu","year":"2017","journal-title":"Neoplasia"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1158\/1078-0432.CCR-16-1662","article-title":"The dual Syk\/JAK inhibitor cerdulatinib antagonizes b-cell receptor and microenvironmental signaling in chronic lymphocytic leukemia","volume":"23","author":"Blunt","year":"2017","journal-title":"Clin. Cancer. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1182\/blood-2015-10-675009","article-title":"BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199","volume":"127","author":"Bojarczuk","year":"2016","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1182\/blood-2009-06-225326","article-title":"The microenvironment in mature B-cell malignancies: A target for new treatment strategies","volume":"114","author":"Burger","year":"2009","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1182\/blood-2015-12-687814","article-title":"High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells","volume":"128","author":"Oppermann","year":"2016","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"59235","DOI":"10.18632\/oncotarget.19494","article-title":"The \u03b3-secretase inhibitors enhance the anti-leukemic activity of ibrutinib in B-CLL cells","volume":"8","author":"Secchiero","year":"2017","journal-title":"Oncotarget"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/leu.2017.175","article-title":"Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL\/SLL","volume":"32","author":"Brown","year":"2018","journal-title":"Leukemia"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S1470-2045(15)00465-9","article-title":"HELIOS investigators, ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): A randomised, double-blind, phase 3 study","volume":"17","author":"Cramer","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2016-06-719294","article-title":"Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia","volume":"129","author":"Ahn","year":"2017","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1182\/blood.2019000854","article-title":"Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: A FILO group study","volume":"134","author":"Quinquenel","year":"2019","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","article-title":"Ibrutinib and Venetoclax for First-Line Treatment of CLL","volume":"380","author":"Jain","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/13543784.2018.1404027","article-title":"Bruton\u2019s tyrosine kinase inhibitors: First and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL)","volume":"27","author":"Thompson","year":"2018","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"70623","DOI":"10.18632\/oncotarget.12139","article-title":"Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia","volume":"7","author":"Voltan","year":"2016","journal-title":"Oncotarget"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1038\/mtna.2014.47","article-title":"Mir-34: A new weapon against cancer?","volume":"3","author":"Misso","year":"2014","journal-title":"Mol. Ther. Nucl. Acids"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nature18288","article-title":"Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells","volume":"534","author":"Abraham","year":"2016","journal-title":"Nature"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"28008","DOI":"10.18632\/oncotarget.15883","article-title":"An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness","volume":"8","author":"Rigolin","year":"2017","journal-title":"Oncotarget"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"7540","DOI":"10.1158\/1078-0432.CCR-19-1009","article-title":"Decreased NOTCH1 Activation Correlates with Response to Ibrutinib in Chronic Lymphocytic Leukemia","volume":"25","author":"Baldoni","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"106423","DOI":"10.1016\/j.leukres.2020.106423","article-title":"Antihistamines are synergistic with Bruton\u2019s tyrosine kinase inhibiter ibrutinib mediated by lysosome disruption in chronic lymphocytic leukemia (CLL) cells","volume":"96","author":"Henson","year":"2020","journal-title":"Leuk. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/s41375-019-0569-7","article-title":"An in vitro assay for biomarker discovery and dose prediction applied to ibrutinib plus venetoclax treatment of CLL","volume":"34","author":"Cremaschi","year":"2020","journal-title":"Leukemia"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1158\/1078-0432.CCR-10-2572","article-title":"Dasatinib plus Nutlin-3 shows synergistic antileukemic activity in both p53 wild-type and p53 mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway","volume":"17","author":"Zauli","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s10637-009-9370-1","article-title":"Perifosine selectively induces cell cycle block and modulates retinoblastoma and E2F1 protein levels in p53 mutated leukemic cell lines","volume":"29","author":"Celeghini","year":"2011","journal-title":"Invest. New Drugs"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"5405","DOI":"10.1158\/0008-5472.CAN-16-0690","article-title":"BTK modulates p53 activity to enhance apoptotic and senescent responses","volume":"76","author":"Althubiti","year":"2016","journal-title":"Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1016\/j.celrep.2016.01.059","article-title":"Therapeutic response to non-genotoxic activation of p53 by nutlin3a is driven by PUMA-mediated apoptosis in lymphoma cells","volume":"14","author":"Valente","year":"2016","journal-title":"Cell Reports"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1158\/2159-8290.CD-15-0507","article-title":"MYC, metabolism, and cancer","volume":"5","author":"Stine","year":"2015","journal-title":"Cancer Discov."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1159\/000492352","article-title":"Membrane-Bound CD40L Promotes Senescence and Initiates Senescence-Associated Secretory Phenotype via NF-\u03baB Activation in Lung Adenocarcinoma","volume":"48","author":"Xu","year":"2018","journal-title":"Cell Physiol. Biochem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrc3702","article-title":"Targeting Bruton\u2019s tyrosine kinase in B cell malignancies","volume":"14","author":"Hendriks","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1038\/onc.2017.95","article-title":"Myc enhances B-cell receptor signaling in precancerous B cells and confers resistance to Btk inhibition","volume":"36","author":"Moyo","year":"2017","journal-title":"Oncogene"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/cdd.2017.143","article-title":"Serine 392 phosphorylation modulates p53 mitochondrial translocation and transcription-independent apoptosis","volume":"25","author":"Castrogiovanni","year":"2018","journal-title":"Cell Death Differ."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"7666","DOI":"10.1093\/nar\/gku501","article-title":"Critical role for p53-serine 15 phosphorylation in stimulating transactivation at p53-responsive promoters","volume":"42","author":"Loughery","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S1534-5807(02)00328-3","article-title":"Survival signaling goes BAD","volume":"3","author":"Bergmann","year":"2002","journal-title":"Dev. Cell"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/cr.2007.19","article-title":"p53 and Bad: Remote strangers become close friends","volume":"17","author":"Jiang","year":"2007","journal-title":"Cell Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1182\/blood-2003-01-0211","article-title":"Cleavage of Bax to p18 Bax accelerates stress-induced apoptosis, and a cathepsin-like protease may rapidly degrade p18 Bax","volume":"102","author":"Cao","year":"2003","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/ajh.24826","article-title":"Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment","volume":"92","author":"Hallek","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTKC481S-mediated resistance to ibrutinib in chronic lymphocytic leukemia","volume":"35","author":"Woyach","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1158\/1535-7163.MCT-16-0511","article-title":"The BTK inhibitor ibrutinib (PCI-32765) overcomes paclitaxel resistance in ABCB1- and ABCC10-overexpressing cells and tumors","volume":"16","author":"Zhang","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.1038\/onc.2015.504","article-title":"A novel oncogenic BTK isoform is overexpressed in colon cancers and required for RAS-mediated transformation","volume":"35","author":"Grassilli","year":"2016","journal-title":"Oncogene"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1080\/15384047.2018.1433500","article-title":"DZNep represses Bcl-2 expression and modulates apoptosis sensitivity in response to Nutlin-3a","volume":"19","author":"Zhou","year":"2018","journal-title":"Cancer Biol. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"987","DOI":"10.3727\/096504018X15424918479652","article-title":"Nutlin-3-induced Sensitization of Non-Small Cell Lung Cancer Stem Cells to Axitinib-Induced Apoptosis through Repression of Akt1\/Wnt Signaling","volume":"27","author":"Wang","year":"2019","journal-title":"Oncol. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.3324\/haematol.2012.062083","article-title":"The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status","volume":"97","author":"Zauli","year":"2012","journal-title":"Haematologica"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/28\/4\/223\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:24:52Z","timestamp":1760163892000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/28\/4\/223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,1]]},"references-count":42,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["curroncol28040223"],"URL":"https:\/\/doi.org\/10.3390\/curroncol28040223","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,1]]}}}